Company Description
Felicitex Therapeutics is a preclinical oncology drug development company focused on developing therapies targeting dormant and active cancer cells.
We have designed and patented small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context.
This approach is lethal to cancer cells that rely on deregulation of the cell cycle for survival and has been shown to lead to the reversal of acquired resistance mechanisms.
Our drug candidates are intended to be effective across a broad range of solid tumors and hematological cancers.
We target a high unmet need in large oncology markets including non-small cell lung cancer, glioblastoma multiforme, ovarian, prostate, colorectal, pancreatic cancers, and acute lymphoblastic leukemia.
To date, our business development efforts have consisted of working to discover and identify new therapeutic compounds through our own proprietary drug discovery platform and in collaboration with third parties, and in advancing what we believe to be the most promising of these compounds through preliminary characterization, validation and efficacy studies, both in vitro and in vivo.
We have not obtained regulatory approval for any of our drug candidates and none has yet entered Phase I clinical trials.
We expect to file 2 Investigational New Drug, or IND, applications during the first half of 2023.
| Country | United States |
| Founded | 2012 |
| Industry | Health Care |
| Sector | Pharmaceuticals |
| Employees | 2 |
| CEO | Maria Vilenchik |
Contact Details
Address: 27 Strathmore Road Natick, MA 01760 United States | |
| Phone | (919) 213-0025 |
| Website | felicitex.com |
Stock Details
| Ticker Symbol | FLCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.25 |
| CIK Code | 0001912287 |
| Employer ID | 81-1036062 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc Duey | Chairman and Director |
| Maria Vilenchik | Chief Executive Officer and Director |
| Arthur Healey | Chief Financial Officer and Secretary |
| Alex Shlyankevich | Director |
| Yuriy Gankin | Director |
| Michael Frid | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 8, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 1, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 31, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 16, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Aug 10, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 28, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 2, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 9, 2022 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 22, 2022 | DRS | [Cover] Draft Registration Statement |